The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction
Authors:
- 25 July 2012
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1263 (1) , 29-40
Abstract
Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function, and survival of osteoclasts. The role of excessive RANKL as a contributor to conditions characterized by bone loss or bone destruction has been well studied. With its novel mechanism of action, denosumab offers a significant advance in the treatment of postmenopausal osteoporosis; bone loss associated with hormone ablation therapy in women with breast cancer and men with prostate cancer; and the prevention of skeletal‐related events in patients with bone metastases from solid tumors by offering clinical benefit to these patients in need.Keywords
This publication has 83 references indexed in Scilit:
- Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in MiceCalcified Tissue International, 2008
- Receptor Activator of NF-κB Ligand Inhibition Suppresses Bone Resorption and Hypercalcemia but Does Not Affect Host Immune Responses to Influenza InfectionThe Journal of Immunology, 2007
- Osteoprotegerin Ligand Modulates Murine Osteoclast Survival in Vitro and in VivoThe American Journal of Pathology, 2000
- RANK is essential for osteoclast and lymph node developmentGenes & Development, 1999
- Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligandProceedings of the National Academy of Sciences, 1999
- OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature, 1999
- osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcificationGenes & Development, 1998
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProceedings of the National Academy of Sciences, 1998
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997